| abstract |
Use of siRNA in the preparation of a medicament for the treatment of an eye condition characterized by an increase in intraocular pressure (IOP), wherein said medication is formulated for topical administration on the surface of the cornea and downregulates the expression of a target gene in the eye, selected from the group consisting of carbonic anhydrases II, IV and XII; adrenergic receptors: beta1 and 2 and alpha 1A, 1B and 1D; acetylcholinesterase; cyclooxygenases 1 and 2; ATPases: alpha1, alpha2, alpha3, beta1, beta2; leukocyte adhesion molecule to endothelium I (ELAM-1); angiotensin II, Angiotensin II Conversion Enzymes (ACE I and ACE II), Angiotensin II Receptors (ATR1 and ATR2) and Renin; Cochlin |